t2c 002Alternative Names: t2c002; t2c002-POAD
Latest Information Update: 06 Oct 2011
At a glance
- Originator t2cure
- Class Anti-ischaemics; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Stem cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Peripheral arterial occlusive disorders
Most Recent Events
- 15 Jan 2009 Phase-I/II clinical trials in Peripheral arterial occlusive disorders in Germany (Intra-arterial)